{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000020","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.465008+00:00","generated_at":"2026-06-20T20:04:24.088206+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"USANA reports preliminary FY2022 net sales ~$995M, EPS ~$3.65; guides FY2023 net sales $850-950M, EPS $2.35-$3.30","bullets":["Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.","Active Customers ~490,000 at year-end; incremental sales in China from COVID policy shift, but uncertainty persists.","Initial FY2023 guidance: net sales $850-950M, diluted EPS $2.35-$3.30, reflecting lower starting customer base and currency headwinds.","Company to report final Q4/FY2022 results on Feb 7, 2023; conference call Feb 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000020","json":"https://secwatch.observer/filing/0001157523-23-000020.json","markdown":"https://secwatch.observer/filing/0001157523-23-000020.md","text":"https://secwatch.observer/filing/0001157523-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/a53173940.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:04:24.088206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"caa24295d95f1d8138fa6aece28c75736e203984","claim":"USANA HEALTH SCIENCES INC reported the full fiscal year ended December 31, 2022 results: revenue approximately $995 million, EPS approximately $3.65.","evidence_excerpt":"The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $995 million"},{"label":"EPS","value":"approximately $3.65"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f255b33d48a93a6ad97a789822a33610f0094ce4","claim":"USANA HEALTH SCIENCES INC reported the fiscal year ending December 30, 2023 results: revenue $850 - $950 million, EPS $2.35 - $3.30. Guidance initiated.","evidence_excerpt":"Initial Fiscal Year 2023 Guidance Consolidated Net Sales $850 - $950 million Diluted EPS $2.35 - $3.30","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending December 30, 2023"},{"label":"Revenue","value":"$850 - $950 million"},{"label":"EPS","value":"$2.35 - $3.30"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}